Deals
BridgeBio Attracts Takeover Interest From Pharma Firms
- Some large pharmas are studying a potential acquisition
- Palo Alto-based biotech could still decide to stay independent
This article is for subscribers only.
BridgeBio Pharma Inc., which develops treatments for genetic diseases, is attracting takeover interest from bigger drug companies, according to people familiar with the matter.
Some large pharmaceutical companies are studying a potential acquisition of the Palo Alto, California-based biotech firm, the people said, asking not to be identified because the information is private.